JO3663B1 - الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين - Google Patents

الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين

Info

Publication number
JO3663B1
JO3663B1 JOP/2015/0192A JOP20150192A JO3663B1 JO 3663 B1 JO3663 B1 JO 3663B1 JO P20150192 A JOP20150192 A JO P20150192A JO 3663 B1 JO3663 B1 JO 3663B1
Authority
JO
Jordan
Prior art keywords
span
fragments
antibodies
antigen
rtl
Prior art date
Application number
JOP/2015/0192A
Other languages
Arabic (ar)
English (en)
Inventor
Liang Linda
De Waal Malefyt Rene
Fayadat-Dilman Laurence
Raghunathan Gopalan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53938468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3663(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of JO3663B1 publication Critical patent/JO3663B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JOP/2015/0192A 2014-08-19 2015-08-11 الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين JO3663B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462039081P 2014-08-19 2014-08-19
US201562171319P 2015-06-05 2015-06-05

Publications (1)

Publication Number Publication Date
JO3663B1 true JO3663B1 (ar) 2020-08-27

Family

ID=53938468

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0192A JO3663B1 (ar) 2014-08-19 2015-08-11 الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين

Country Status (40)

Country Link
US (6) US20170290914A1 (enExample)
EP (2) EP3182999B1 (enExample)
JP (3) JP2017532059A (enExample)
KR (2) KR102321166B1 (enExample)
CN (1) CN107001470B (enExample)
AP (1) AP2017009763A0 (enExample)
AU (3) AU2015305770C1 (enExample)
BR (1) BR112017003194B8 (enExample)
CA (2) CA3082655A1 (enExample)
CL (1) CL2017000311A1 (enExample)
CO (1) CO2017001558A2 (enExample)
CR (1) CR20170059A (enExample)
CY (1) CY1124252T1 (enExample)
DK (1) DK3182999T3 (enExample)
DO (1) DOP2017000047A (enExample)
ES (1) ES2857505T3 (enExample)
GE (1) GEP20227343B (enExample)
GT (1) GT201700034A (enExample)
HR (1) HRP20210372T1 (enExample)
HU (1) HUE053641T2 (enExample)
IL (2) IL297053A (enExample)
JO (1) JO3663B1 (enExample)
LT (1) LT3182999T (enExample)
MA (2) MA40476B1 (enExample)
MD (1) MD4716C1 (enExample)
MX (2) MX377753B (enExample)
MY (1) MY187262A (enExample)
NI (1) NI201700018A (enExample)
PE (1) PE20170288A1 (enExample)
PH (1) PH12017500297B1 (enExample)
PL (1) PL3182999T3 (enExample)
PT (1) PT3182999T (enExample)
RS (1) RS61559B1 (enExample)
SG (1) SG11201701090VA (enExample)
SI (1) SI3182999T1 (enExample)
TN (1) TN2017000025A1 (enExample)
TW (3) TWI742395B (enExample)
UA (2) UA119571C2 (enExample)
WO (1) WO2016028672A1 (enExample)
ZA (2) ZA201700956B (enExample)

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
LT3081576T (lt) 2013-12-12 2019-10-25 Shanghai hengrui pharmaceutical co ltd Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3116909B1 (en) 2014-03-14 2019-11-13 Novartis Ag Antibody molecules to lag-3 and uses thereof
TN2017000532A1 (en) 2014-03-28 2019-04-12 Xencor Inc Bispecific antibodies that bind to cd38 and cd3.
IL293212B2 (en) 2014-05-28 2023-12-01 Memorial Sloan Kettering Cancer Center Anti-GITR antibodies and methods of using them
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AU2015314756A1 (en) 2014-09-13 2017-03-16 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) * 2014-10-03 2020-10-14 Novartis AG Combination therapies
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CN107406512A (zh) 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
BR112017011092A2 (pt) 2014-11-26 2017-12-26 Xencor Inc anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
MA42459A (fr) * 2015-07-16 2018-05-23 Bioxcel Therapeutics Inc Nouvelle approche pour le traitement du cancer par immunomodulation
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
PL3356411T3 (pl) 2015-10-02 2021-12-06 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste swoiste dla PD1 i TIM3
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
CR20180318A (es) 2015-12-14 2018-09-19 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
KR20180086502A (ko) * 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
WO2017143451A1 (en) * 2016-02-26 2017-08-31 Western University Anti-cd11d antibodies and uses thereof
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
PL3458478T3 (pl) * 2016-05-18 2021-06-28 Boehringer Ingelheim International Gmbh Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
MY195089A (en) 2016-05-27 2023-01-10 Agenus Inc Anti-Tim-3 Antibodies and Methods of use thereof
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
EP3468586B1 (en) 2016-06-14 2024-08-07 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
DK3472207T3 (da) 2016-06-20 2021-04-12 F Star Delta Ltd Bindingsmolekyler, der binder pd-l1 og lag-3
CN109311993B (zh) 2016-06-20 2022-12-20 F-星治疗有限公司 Lag-3结合元件
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN108472349B (zh) * 2016-06-23 2022-05-24 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
KR102340687B1 (ko) * 2016-08-15 2021-12-16 국립대학법인 홋가이도 다이가쿠 항 lag-3 항체
LT3347379T (lt) 2016-08-17 2020-05-11 Compugen Ltd. Anti-tigit antikūnai, anti-pvrig antikūnai ir jų kombinacijos
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN109689870B (zh) * 2016-09-08 2022-11-29 第一三共株式会社 用于治疗自身免疫疾病的抗体
IL265800B2 (en) 2016-10-11 2023-10-01 Agenus Inc Anti-LAG-3 antibodies and methods of using them
AU2017342071B2 (en) * 2016-10-13 2024-11-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Anti-LAG-3 antibodies and compositions
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
US12162938B2 (en) * 2016-10-28 2024-12-10 Merck Sharp & Dohme Llc Purification process for removal of tyrosine sulfation antibody variants; purified compositions
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
PT3551660T (pt) 2016-12-07 2023-11-30 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
BR112019013940A2 (pt) * 2017-01-06 2020-02-11 Iovance Biotherapeutics, Inc. Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
JP6929951B2 (ja) * 2017-02-22 2021-09-01 アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｌａｇ−３抗体およびその使用
EP3606946B1 (en) 2017-04-03 2022-08-24 F. Hoffmann-La Roche AG Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
IL268527B2 (en) 2017-04-05 2024-03-01 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
DK3606954T3 (en) * 2017-04-05 2022-09-26 Hoffmann La Roche Anti-LAG3-antistoffer
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
BR112019022515A2 (pt) * 2017-04-27 2020-06-16 Tesaro, Inc. Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11339218B2 (en) 2017-05-10 2022-05-24 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against LAG3 and uses thereof
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
PT3631454T (pt) 2017-05-30 2023-11-23 Bristol Myers Squibb Co Tratamento de tumores positivos para lag-3
AU2018277559A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
US20230042913A1 (en) * 2017-06-05 2023-02-09 The Council Of The Queensland Institute Of Medical Research A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
JP2020525483A (ja) 2017-06-27 2020-08-27 ノバルティス アーゲー 抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
CN111094350B (zh) * 2017-07-06 2024-09-03 美勒斯公司 调节由细胞表达的生物活性的抗体
JP6896989B2 (ja) * 2017-07-13 2021-06-30 ナンジン リーズ バイオラブズ カンパニー リミテッド 抗体結合ｌａｇ−３及びその使用
IL319798A (en) 2017-07-20 2025-05-01 Novartis Ag ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
KR20200042937A (ko) * 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
WO2019094637A1 (en) * 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
WO2019099597A2 (en) 2017-11-17 2019-05-23 Merck Sharp & Dohme Corp. Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
CN111741976B (zh) 2017-12-19 2024-09-17 英沃克斯制药有限公司 包括pd-l1抗原结合位点的fc结合片段
CA3085656A1 (en) * 2017-12-22 2019-06-27 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody pharmaceutical composition and use thereof
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN115925943A (zh) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
CN111542546B (zh) * 2018-01-18 2022-08-16 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
CN108085393B (zh) * 2018-01-31 2020-06-02 青岛泱深生物医药有限公司 肾透明细胞癌相关生物标志物及其应用
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US20210363243A1 (en) * 2018-02-01 2021-11-25 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
ES2986967T3 (es) 2018-02-08 2024-11-13 Dragonfly Therapeutics Inc Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
BR112020016939A2 (pt) 2018-02-20 2020-12-15 Dragonfly Therapeutics, Inc. Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso
CN110305215B (zh) * 2018-03-20 2023-11-03 基石药业 新型抗lag-3抗体多肽
WO2019179365A1 (en) 2018-03-20 2019-09-26 WuXi Biologics Ireland Limited Novel anti-lag-3 antibody polypeptide
KR102825164B1 (ko) 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
KR102876940B1 (ko) 2018-03-30 2025-10-24 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
JP7104458B2 (ja) * 2018-04-02 2022-07-21 上海博威生物医薬有限公司 リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
EP3774921A4 (en) * 2018-04-03 2022-01-05 Dragonfly Therapeutics, Inc. ANTIBODY VARIABLE DOMAINS AGAINST DLL3 AND USE OF IT
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
WO2019210848A1 (en) 2018-05-03 2019-11-07 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
MX2021000309A (es) 2018-07-10 2021-04-12 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-dion a y su uso en el tratamiento de enfermedades dependientes del dedo de zinc 2 de la familia ikaros (ikzf2).
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
EP4512417A3 (en) 2018-07-12 2025-09-17 invoX Pharma Limited Antibody molecules that bind pd-l1 and cd137
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
KR20210040080A (ko) 2018-07-26 2021-04-12 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 lag-3 조합 요법
SG11202100883SA (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
WO2020038397A1 (en) * 2018-08-21 2020-02-27 I-Mab Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
EP3849606A4 (en) * 2018-09-13 2022-06-29 Merck Sharp & Dohme Corp. Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CA3117016A1 (en) 2018-10-19 2020-04-23 Bristol-Myers Squibb Company Combination therapy for melanoma
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
EP3880709A4 (en) * 2018-11-05 2022-07-27 Merck Sharp & Dohme Corp. DOSING REGIME OF ANTI-LAG3 ANTIBODIES AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER
KR20210089215A (ko) * 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020127965A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
EP3898674A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
BR112021011351A2 (pt) 2018-12-21 2021-11-16 Novartis Ag Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
SG11202109406TA (en) 2019-03-01 2021-09-29 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
JP7547360B2 (ja) 2019-03-22 2024-09-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
EP3947640A4 (en) 2019-04-02 2022-12-14 The Brigham & Women's Hospital, Inc. PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
WO2020216383A1 (en) * 2019-04-26 2020-10-29 Single Cell Technology, Inc. Anti-lag-3 antibodies
WO2020236667A1 (en) * 2019-05-17 2020-11-26 Gb006, Inc. Methods of treating cancer
AU2020279371A1 (en) 2019-05-22 2021-12-23 Leidos, Inc. LAG 3 binding peptides
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
BR112021026559A2 (pt) * 2019-07-17 2022-02-15 Noxopharm Ltd Terapia imuno-oncológica usando compostos isoflavona
EP4003523A4 (en) * 2019-07-30 2023-09-06 Merck Sharp & Dohme LLC ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
BR112022004316A2 (pt) 2019-09-22 2022-06-21 Bristol Myers Squibb Co Caracterização espacial quantitativa para terapia de antagonista lag-3
MX2022004766A (es) 2019-10-21 2022-05-16 Novartis Ag Terapias combinadas con venetoclax e inhibidores de tim-3.
KR20220087498A (ko) 2019-10-21 2022-06-24 노파르티스 아게 Tim-3 억제제 및 그의 용도
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
KR20220093349A (ko) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
CA3160526A1 (en) * 2019-11-11 2021-05-20 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
IL293834A (en) 2019-12-20 2022-08-01 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US20230333090A1 (en) * 2019-12-20 2023-10-19 Merck Sharp & Dohme Llc Lag3 antagonist cell based potency assay
KR20220128389A (ko) 2020-01-17 2022-09-20 노파르티스 아게 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
KR20220131279A (ko) * 2020-01-21 2022-09-27 상하이 헨리우스 바이오테크, 인크. 항lag3단일 클론 항체 및 그 제조 방법과 응용
JP2023512991A (ja) * 2020-01-29 2023-03-30 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体生成からの宿主細胞リパーゼの分離方法
US20230087600A1 (en) 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
KR102245082B1 (ko) * 2020-02-14 2021-04-26 단국대학교 천안캠퍼스 산학협력단 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
EP4138889A4 (en) * 2020-04-21 2025-05-21 Board of Regents, The University of Texas System METHODS OF TREATMENT OF BLADDER CANCER
EP4138847A4 (en) * 2020-04-24 2024-05-22 Memorial Sloan Kettering Cancer Center Targeted therapy for the treatment & prevention of life-threatening complications of infection
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US11338040B2 (en) 2020-06-04 2022-05-24 Leidos, Inc. Immunomodulatory compounds
CN111808192B (zh) * 2020-06-05 2022-02-15 北京天广实生物技术股份有限公司 结合lag3的抗体及其用途
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
JP2023536466A (ja) 2020-07-31 2023-08-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022047189A1 (en) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
MX2023004493A (es) 2020-10-23 2023-05-10 Bristol Myers Squibb Co Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon.
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022109987A1 (en) * 2020-11-27 2022-06-02 Shanghai Benemae Pharmaceutical Corporation Novel anti-lag3 antibodies and methods of making and using the same
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CN114621345B (zh) * 2020-12-10 2022-11-29 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
DK4267105T3 (da) 2020-12-28 2025-05-19 Bristol Myers Squibb Co Antistofsammensætninger og fremgangsmåder til anvendelse deraf
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
KR20230150295A (ko) 2021-01-29 2023-10-30 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키나제 억제제를 이용한 암의 치료 방법
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
AR125037A1 (es) * 2021-03-08 2023-05-31 Medimmune Llc Anticuerpos dirigidos contra gdf-15
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
JP2024514245A (ja) 2021-03-29 2024-03-29 ジュノー セラピューティクス インコーポレイテッド チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216979A1 (en) 2021-04-08 2022-10-13 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN115403670A (zh) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
CN115611983A (zh) 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
CA3229021A1 (en) * 2021-08-17 2023-02-23 William Winston Inducible il-2 and pd-1/pd-l1 combination therapy
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
US20240417473A1 (en) 2021-10-29 2024-12-19 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
TW202334218A (zh) * 2021-11-01 2023-09-01 中國大陸商科望（蘇州）生物醫藥科技有限公司 新型抗ｌａｇ３抗體
IL313439A (en) 2021-12-16 2024-08-01 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
MX2024008831A (es) 2022-01-26 2024-07-25 Bristol Myers Squibb Co Terapia combinada para carcinoma hepatocelular.
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
CN118765284A (zh) 2022-02-25 2024-10-11 百时美施贵宝公司 结直肠癌的组合疗法
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
US20250179170A1 (en) 2022-03-08 2025-06-05 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
CR20240379A (es) 2022-03-15 2024-12-11 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia combinada en el tratamiento del cáncer
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CA3258064A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
WO2024102603A1 (en) * 2022-11-07 2024-05-16 Merck Sharp & Dohme Llc Bisecting-glycan bridged conjugation for producing glycoprotein conjugates
CN120390652A (zh) 2022-12-01 2025-07-29 免疫医疗有限公司 用于治疗癌症的包含抗pd-l1抗体和抗cd73抗体的组合疗法
EP4634224A1 (en) 2022-12-14 2025-10-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
AU2023409221A1 (en) 2022-12-21 2025-06-12 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
AU2024225483A1 (en) 2023-02-23 2025-08-28 Imcheck Therapeutics Combination of btn3a activating antibody and immune checkpoint inhibitors
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025054110A1 (en) * 2023-09-07 2025-03-13 Merck Sharp & Dohme Llc Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with cancer before and/or after surgery
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
TW202535926A (zh) 2023-10-30 2025-09-16 美商再生元醫藥公司 穩定抗體配製物
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
TW202539744A (zh) 2024-02-27 2025-10-16 美商必治妥美雅史谷比公司 抗ｃｅａｃａｍ５抗體藥物軛合物
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025226695A1 (en) 2024-04-23 2025-10-30 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US778A (en) 1838-06-12 Thomas wright
US4946A (en) 1847-01-26 Improvement in carriage-wheels
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2338321T3 (es) 1992-08-21 2010-05-06 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
IL113617A (en) 1994-05-06 2007-09-20 Florence Faure Use of LAG-3 antibodies to prepare a therapeutic agent that stimulates the immune system
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DK0843557T3 (da) 1995-07-21 2003-03-10 Inst Nat Sante Rech Med Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein
JP2000516101A (ja) 1996-11-28 2000-12-05 アンスティテュ ギュスタブ ルシ Ｌａｇ−３タンパク質の変異体、その発現及び使用
EP0941329B1 (en) 1996-11-29 2004-07-21 Applied Research Systems ARS Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
KR100483494B1 (ko) 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
CA2412701A1 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
SE0103423D0 (sv) 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
PL1897548T5 (pl) 2003-02-28 2025-03-17 The Johns Hopkins University Regulacja komórek T
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
WO2008021156A2 (en) 2006-08-11 2008-02-21 Schering Corporation Antibodies to il-17a
KR20090088950A (ko) 2006-12-14 2009-08-20 쉐링 코포레이션 가공된 항-ｔｓｌｐ 항체
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011005396A (es) * 2008-11-25 2011-06-09 Alder Biopharmaceuticals Inc Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp.
PE20120415A1 (es) * 2008-12-12 2012-05-09 Boehringer Ingelheim Int Anticuerpos anti-igf
CA2791383C (en) 2010-03-05 2022-09-20 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
JP5503520B2 (ja) 2010-12-22 2014-05-28 新電元工業株式会社 制御回路
US9132281B2 (en) 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
LT2726101T (lt) 2011-06-30 2018-11-26 Genzyme Corporation T ląstelių aktyvinimo slopikliai
AU2012332840A1 (en) 2011-10-31 2014-05-15 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
WO2013066765A1 (en) 2011-11-01 2013-05-10 Merck Sharp & Dohme Corp. Mutation of tup1 in glycoengineered yeast
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
WO2013192215A1 (en) 2012-06-18 2013-12-27 Yale University Compositions and methods for diminishing an immune response
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
CA2882223A1 (en) 2012-08-21 2014-02-27 Glaxo Group Limited Compositions comprising an antibody and camostat mesylate (cm)
KR20150043342A (ko) 2012-08-21 2015-04-22 글락소 그룹 리미티드 단일 가변 도메인 및 카모스타트 메실레이트 (cm)를 포함하는 조성물
WO2014105810A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
MX2015011075A (es) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Peptidos terapeuticos.
US10344088B2 (en) 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
EP2981281B1 (en) 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN105339389B (zh) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
BR112016001420A2 (pt) 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
EA036902B1 (ru) 2013-09-20 2021-01-13 Бристол-Майерс Сквибб Компани Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3065772B1 (en) 2013-11-05 2024-07-24 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
KR102395820B1 (ko) 2013-11-05 2022-05-09 버베리안 노딕 에이/에스 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제
CN106029694A (zh) 2013-12-06 2016-10-12 达纳-法伯癌症研究院公司 治疗性肽
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
SI3556775T1 (sl) 2014-01-28 2022-02-28 Bristol-Myers Squibb Company Protitelesa proti-LAG-3 za zdravljenje hematoloških malignosti
EP3116909B1 (en) 2014-03-14 2019-11-13 Novartis Ag Antibody molecules to lag-3 and uses thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2929532T3 (es) 2015-01-29 2022-11-30 Univ Pennsylvania Combinaciones de inhibidores de puntos de control y vacunas y su uso en inmunoterapia
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
KR102740444B1 (ko) 2015-04-17 2024-12-10 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI733687B (zh) 2015-07-22 2021-07-21 美商索倫多醫療公司 結合ｌａｇ３之抗體治療劑
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies

Also Published As

Publication number Publication date
MA40476B1 (fr) 2021-03-31
US20170290914A1 (en) 2017-10-12
CN107001470B (zh) 2021-06-22
AP2017009763A0 (en) 2016-02-28
CY1124252T1 (el) 2022-07-22
TWI742395B (zh) 2021-10-11
AU2015305770B2 (en) 2018-09-13
US20190083615A1 (en) 2019-03-21
EP3834842A1 (en) 2021-06-16
IL250566A0 (en) 2017-03-30
JP2018183173A (ja) 2018-11-22
US20170267759A1 (en) 2017-09-21
TW201613979A (en) 2016-04-16
AU2018278910A1 (en) 2019-01-03
GT201700034A (es) 2019-10-10
DK3182999T3 (da) 2021-03-15
PT3182999T (pt) 2021-03-01
MX377753B (es) 2025-03-11
MY187262A (en) 2021-09-16
ES2857505T3 (es) 2021-09-29
JP2017532059A (ja) 2017-11-02
PH12017500297B1 (en) 2023-07-19
ZA202003742B (en) 2022-08-31
MX2017002230A (es) 2017-05-09
AU2015305770A1 (en) 2017-03-09
KR102321166B1 (ko) 2021-11-02
MX2019005426A (es) 2023-04-27
EP3182999A1 (en) 2017-06-28
GEP20227343B (en) 2022-01-25
IL250566B (en) 2022-11-01
ZA201700956B (en) 2022-05-25
AU2020230256A1 (en) 2020-10-01
UA127888C2 (uk) 2024-02-07
IL250566B2 (en) 2023-03-01
CN107001470A (zh) 2017-08-01
CL2017000311A1 (es) 2017-08-18
US10898571B2 (en) 2021-01-26
MA40476A (fr) 2017-06-28
NZ729160A (en) 2024-08-30
KR102037197B1 (ko) 2019-10-28
HRP20210372T1 (hr) 2021-07-09
LT3182999T (lt) 2021-03-25
BR112017003194B8 (pt) 2023-04-18
US11278620B2 (en) 2022-03-22
WO2016028672A1 (en) 2016-02-25
CA3082655A1 (en) 2016-02-25
MA55347A (fr) 2022-01-26
HUE053641T2 (hu) 2021-07-28
US20220257762A1 (en) 2022-08-18
JP6843174B2 (ja) 2021-03-17
TW201938589A (zh) 2019-10-01
CA2957275C (en) 2020-08-25
CO2017001558A2 (es) 2017-07-19
PL3182999T3 (pl) 2021-05-31
SI3182999T1 (sl) 2021-04-30
EP3182999B1 (en) 2021-01-06
UA119571C2 (uk) 2019-07-10
BR112017003194A2 (pt) 2017-11-28
MD20170031A2 (ro) 2017-07-31
SG11201701090VA (en) 2017-03-30
US20190091332A1 (en) 2019-03-28
KR20170043589A (ko) 2017-04-21
AU2015305770C1 (en) 2024-08-01
TWI698448B (zh) 2020-07-11
BR112017003194B1 (pt) 2020-06-09
CA2957275A1 (en) 2016-02-25
MD4716B1 (ro) 2020-10-31
PH12017500297A1 (en) 2017-07-17
MD4716C1 (ro) 2021-05-31
AU2020230256B2 (en) 2024-01-18
US10188730B2 (en) 2019-01-29
IL297053A (en) 2022-12-01
DOP2017000047A (es) 2017-05-15
NZ766804A (en) 2024-08-30
CR20170059A (es) 2017-04-28
JP2019122405A (ja) 2019-07-25
US11207406B2 (en) 2021-12-28
TN2017000025A1 (en) 2018-07-04
KR20190122881A (ko) 2019-10-30
US12102681B2 (en) 2024-10-01
JP6538247B2 (ja) 2019-07-03
NI201700018A (es) 2017-03-08
PE20170288A1 (es) 2017-04-05
TWI673286B (zh) 2019-10-01
RS61559B1 (sr) 2021-04-29
US20190083614A1 (en) 2019-03-21
TW201920284A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
JO3663B1 (ar) الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CU20170169A7 (es) Anticuerpos de factor xi
MX2018007406A (es) Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
SA522431756B1 (ar) Tigit أجسام مضادة لـ
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
GEP20217220B (en) Pd1 and/or lag3 binders
PH12017500890A1 (en) Antibody drug conjugates
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
MX2015016978A (es) Proteinas de union a antigeno neutralizantes de citomegalovirus.
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA201590918A1 (ru) Антитела к bmp-6
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201990218A1 (ru) Антитела с низкой иммуногенностью и их применения
EA201591898A1 (ru) Антитела, направленные на m-csf
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения
EA201790403A1 (ru) Антитела против lag3 и антигенсвязывающие фрагменты
TH1501000960A (th) แอนติบอดีและวัคซีนสำหรับใช้ในการรักษามะเร็ง ror1 และยับยั้งการแพร่กระจาย